Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline Market The MA And Commercial Landscape
Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline & Market: The M&A And Commercial Landscape By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors In Part 1 and Part 2 of this three-part series, we covered the varied complexities of NASH driving an extremely challenging development landscape, along with the growing prevalence of NASH that has the life sciences industry in a race to develop a successful asset. In this last part of the series, we cover the M&A and commercial landscape implications, including historical and future deal trends,...
Source: bioprocessonline.com